IBDEI03R ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4680,0)
 ;;=258.1^^45^386^15
 ;;^UTILITY(U,$J,358.3,4680,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4680,1,4,0)
 ;;=4^POLYGLANDULAR FAILURE
 ;;^UTILITY(U,$J,358.3,4680,1,5,0)
 ;;=5^258.1
 ;;^UTILITY(U,$J,358.3,4680,2)
 ;;=^267892
 ;;^UTILITY(U,$J,358.3,4681,0)
 ;;=626.0^^45^386^1
 ;;^UTILITY(U,$J,358.3,4681,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4681,1,4,0)
 ;;=4^AMENORRHEA
 ;;^UTILITY(U,$J,358.3,4681,1,5,0)
 ;;=5^626.0
 ;;^UTILITY(U,$J,358.3,4681,2)
 ;;=^5871
 ;;^UTILITY(U,$J,358.3,4682,0)
 ;;=628.0^^45^386^2
 ;;^UTILITY(U,$J,358.3,4682,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4682,1,4,0)
 ;;=4^ANOVULATION,INFERTILITY
 ;;^UTILITY(U,$J,358.3,4682,1,5,0)
 ;;=5^628.0
 ;;^UTILITY(U,$J,358.3,4682,2)
 ;;=^270583
 ;;^UTILITY(U,$J,358.3,4683,0)
 ;;=626.5^^45^386^12
 ;;^UTILITY(U,$J,358.3,4683,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4683,1,4,0)
 ;;=4^OVULATION BLEEDING
 ;;^UTILITY(U,$J,358.3,4683,1,5,0)
 ;;=5^626.5
 ;;^UTILITY(U,$J,358.3,4683,2)
 ;;=^270570
 ;;^UTILITY(U,$J,358.3,4684,0)
 ;;=627.1^^45^386^16
 ;;^UTILITY(U,$J,358.3,4684,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4684,1,4,0)
 ;;=4^POSTMENOPAUSAL BLEEDING
 ;;^UTILITY(U,$J,358.3,4684,1,5,0)
 ;;=5^627.1
 ;;^UTILITY(U,$J,358.3,4684,2)
 ;;=^97040
 ;;^UTILITY(U,$J,358.3,4685,0)
 ;;=617.9^^45^386^4
 ;;^UTILITY(U,$J,358.3,4685,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4685,1,4,0)
 ;;=4^ENDOMETRIOSIS NOS
 ;;^UTILITY(U,$J,358.3,4685,1,5,0)
 ;;=5^617.9
 ;;^UTILITY(U,$J,358.3,4685,2)
 ;;=^40463
 ;;^UTILITY(U,$J,358.3,4686,0)
 ;;=628.9^^45^386^5
 ;;^UTILITY(U,$J,358.3,4686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4686,1,4,0)
 ;;=4^FEMALE INFERTILITY NOS
 ;;^UTILITY(U,$J,358.3,4686,1,5,0)
 ;;=5^628.9
 ;;^UTILITY(U,$J,358.3,4686,2)
 ;;=^62820
 ;;^UTILITY(U,$J,358.3,4687,0)
 ;;=611.6^^45^386^6
 ;;^UTILITY(U,$J,358.3,4687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4687,1,4,0)
 ;;=4^GALACTORRHEA-NONOBSTET
 ;;^UTILITY(U,$J,358.3,4687,1,5,0)
 ;;=5^611.6
 ;;^UTILITY(U,$J,358.3,4687,2)
 ;;=^270460
 ;;^UTILITY(U,$J,358.3,4688,0)
 ;;=256.1^^45^386^11
 ;;^UTILITY(U,$J,358.3,4688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4688,1,4,0)
 ;;=4^OVARIAN HYPERFUNC NEC
 ;;^UTILITY(U,$J,358.3,4688,1,5,0)
 ;;=5^256.1
 ;;^UTILITY(U,$J,358.3,4688,2)
 ;;=^267878
 ;;^UTILITY(U,$J,358.3,4689,0)
 ;;=704.1^^45^386^7
 ;;^UTILITY(U,$J,358.3,4689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4689,1,4,0)
 ;;=4^HIRSUTISM
 ;;^UTILITY(U,$J,358.3,4689,1,5,0)
 ;;=5^704.1
 ;;^UTILITY(U,$J,358.3,4689,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,4690,0)
 ;;=627.2^^45^386^9
 ;;^UTILITY(U,$J,358.3,4690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4690,1,4,0)
 ;;=4^MENOPAUSE
 ;;^UTILITY(U,$J,358.3,4690,1,5,0)
 ;;=5^627.2
 ;;^UTILITY(U,$J,358.3,4690,2)
 ;;=^328735
 ;;^UTILITY(U,$J,358.3,4691,0)
 ;;=256.31^^45^386^8
 ;;^UTILITY(U,$J,358.3,4691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4691,1,4,0)
 ;;=4^MANOPAUSE,PREMATURE
 ;;^UTILITY(U,$J,358.3,4691,1,5,0)
 ;;=5^256.31
 ;;^UTILITY(U,$J,358.3,4691,2)
 ;;=^75883
 ;;^UTILITY(U,$J,358.3,4692,0)
 ;;=256.39^^45^386^10
 ;;^UTILITY(U,$J,358.3,4692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4692,1,4,0)
 ;;=4^OTHER OVARIAN FAILURE
 ;;^UTILITY(U,$J,358.3,4692,1,5,0)
 ;;=5^256.39
 ;;^UTILITY(U,$J,358.3,4692,2)
 ;;=^330824
 ;;^UTILITY(U,$J,358.3,4693,0)
 ;;=256.4^^45^386^13
 ;;^UTILITY(U,$J,358.3,4693,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4693,1,4,0)
 ;;=4^POLYCYSTIC OVARIES
 ;;^UTILITY(U,$J,358.3,4693,1,5,0)
 ;;=5^256.4
 ;;^UTILITY(U,$J,358.3,4693,2)
 ;;=^96086
 ;;^UTILITY(U,$J,358.3,4694,0)
 ;;=616.10^^45^386^17
 ;;^UTILITY(U,$J,358.3,4694,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4694,1,4,0)
 ;;=4^VAGINITIS NOS
 ;;^UTILITY(U,$J,358.3,4694,1,5,0)
 ;;=5^616.10
 ;;^UTILITY(U,$J,358.3,4694,2)
 ;;=^125233
 ;;^UTILITY(U,$J,358.3,4695,0)
 ;;=627.3^^45^386^18
 ;;^UTILITY(U,$J,358.3,4695,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4695,1,4,0)
 ;;=4^VAGINITIS,ATROPHIC
 ;;^UTILITY(U,$J,358.3,4695,1,5,0)
 ;;=5^627.3
 ;;^UTILITY(U,$J,358.3,4695,2)
 ;;=^270577
 ;;^UTILITY(U,$J,358.3,4696,0)
 ;;=112.1^^45^386^19
 ;;^UTILITY(U,$J,358.3,4696,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4696,1,4,0)
 ;;=4^VAGINITIS,CANDIDAL
 ;;^UTILITY(U,$J,358.3,4696,1,5,0)
 ;;=5^112.1
 ;;^UTILITY(U,$J,358.3,4696,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,4697,0)
 ;;=131.01^^45^386^20
 ;;^UTILITY(U,$J,358.3,4697,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4697,1,4,0)
 ;;=4^VAGINITIS,TRICHOMONAL
 ;;^UTILITY(U,$J,358.3,4697,1,5,0)
 ;;=5^131.01
 ;;^UTILITY(U,$J,358.3,4697,2)
 ;;=^121763
 ;;^UTILITY(U,$J,358.3,4698,0)
 ;;=193.^^45^387^12
 ;;^UTILITY(U,$J,358.3,4698,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4698,1,4,0)
 ;;=4^THYROID CANCER
 ;;^UTILITY(U,$J,358.3,4698,1,5,0)
 ;;=5^193.
 ;;^UTILITY(U,$J,358.3,4698,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,4699,0)
 ;;=240.9^^45^387^3
 ;;^UTILITY(U,$J,358.3,4699,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4699,1,4,0)
 ;;=4^GOITER NOS
 ;;^UTILITY(U,$J,358.3,4699,1,5,0)
 ;;=5^240.9
 ;;^UTILITY(U,$J,358.3,4699,2)
 ;;=^52400
 ;;^UTILITY(U,$J,358.3,4700,0)
 ;;=241.1^^45^387^7
 ;;^UTILITY(U,$J,358.3,4700,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4700,1,4,0)
 ;;=4^MULTINODULAR
 ;;^UTILITY(U,$J,358.3,4700,1,5,0)
 ;;=5^241.1
 ;;^UTILITY(U,$J,358.3,4700,2)
 ;;=^267790
 ;;^UTILITY(U,$J,358.3,4701,0)
 ;;=242.20^^45^387^8
 ;;^UTILITY(U,$J,358.3,4701,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4701,1,4,0)
 ;;=4^MULTINODULAR,TOXIC
 ;;^UTILITY(U,$J,358.3,4701,1,5,0)
 ;;=5^242.20
 ;;^UTILITY(U,$J,358.3,4701,2)
 ;;=^267801
 ;;^UTILITY(U,$J,358.3,4702,0)
 ;;=242.00^^45^387^4
 ;;^UTILITY(U,$J,358.3,4702,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4702,1,4,0)
 ;;=4^GRAVES DISEASE
 ;;^UTILITY(U,$J,358.3,4702,1,5,0)
 ;;=5^242.00
 ;;^UTILITY(U,$J,358.3,4702,2)
 ;;=^267793
 ;;^UTILITY(U,$J,358.3,4703,0)
 ;;=244.9^^45^387^5
 ;;^UTILITY(U,$J,358.3,4703,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4703,1,4,0)
 ;;=4^HYPOTHYROIDISM NOS
 ;;^UTILITY(U,$J,358.3,4703,1,5,0)
 ;;=5^244.9
 ;;^UTILITY(U,$J,358.3,4703,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,4704,0)
 ;;=244.1^^45^387^9
 ;;^UTILITY(U,$J,358.3,4704,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4704,1,4,0)
 ;;=4^POST I-131
 ;;^UTILITY(U,$J,358.3,4704,1,5,0)
 ;;=5^244.1
 ;;^UTILITY(U,$J,358.3,4704,2)
 ;;=^267816
 ;;^UTILITY(U,$J,358.3,4705,0)
 ;;=244.0^^45^387^10
 ;;^UTILITY(U,$J,358.3,4705,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4705,1,4,0)
 ;;=4^POSTSURGICAL HYPOTHYROID
 ;;^UTILITY(U,$J,358.3,4705,1,5,0)
 ;;=5^244.0
 ;;^UTILITY(U,$J,358.3,4705,2)
 ;;=^267814
 ;;^UTILITY(U,$J,358.3,4706,0)
 ;;=246.0^^45^387^6
 ;;^UTILITY(U,$J,358.3,4706,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4706,1,4,0)
 ;;=4^HYPR,THRYOCALCITONIN
 ;;^UTILITY(U,$J,358.3,4706,1,5,0)
 ;;=5^246.0
 ;;^UTILITY(U,$J,358.3,4706,2)
 ;;=^267827
 ;;^UTILITY(U,$J,358.3,4707,0)
 ;;=241.0^^45^387^13
 ;;^UTILITY(U,$J,358.3,4707,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4707,1,4,0)
 ;;=4^THYROID NODULE
 ;;^UTILITY(U,$J,358.3,4707,1,5,0)
 ;;=5^241.0
 ;;^UTILITY(U,$J,358.3,4707,2)
 ;;=^83865
 ;;^UTILITY(U,$J,358.3,4708,0)
 ;;=242.10^^45^387^14
 ;;^UTILITY(U,$J,358.3,4708,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4708,1,4,0)
 ;;=4^THYROID NODULE,HOT
 ;;^UTILITY(U,$J,358.3,4708,1,5,0)
 ;;=5^242.10
 ;;^UTILITY(U,$J,358.3,4708,2)
 ;;=^267797
 ;;^UTILITY(U,$J,358.3,4709,0)
 ;;=245.0^^45^387^1
 ;;^UTILITY(U,$J,358.3,4709,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4709,1,4,0)
 ;;=4^ACUTE THYROIDITIS
 ;;^UTILITY(U,$J,358.3,4709,1,5,0)
 ;;=5^245.0
 ;;^UTILITY(U,$J,358.3,4709,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,4710,0)
 ;;=245.2^^45^387^2
 ;;^UTILITY(U,$J,358.3,4710,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4710,1,4,0)
 ;;=4^CHR LYMPHOCYT THYROIDIT
 ;;^UTILITY(U,$J,358.3,4710,1,5,0)
 ;;=5^245.2
 ;;^UTILITY(U,$J,358.3,4710,2)
 ;;=^119344
 ;;^UTILITY(U,$J,358.3,4711,0)
 ;;=245.1^^45^387^11
 ;;^UTILITY(U,$J,358.3,4711,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4711,1,4,0)
 ;;=4^SUBACUTE THYROIDITIS
 ;;^UTILITY(U,$J,358.3,4711,1,5,0)
 ;;=5^245.1
 ;;^UTILITY(U,$J,358.3,4711,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,4712,0)
 ;;=252.1^^45^387^15
 ;;^UTILITY(U,$J,358.3,4712,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4712,1,4,0)
 ;;=4^HYPOPARATHYROIDISM
 ;;^UTILITY(U,$J,358.3,4712,1,5,0)
 ;;=5^252.1
 ;;^UTILITY(U,$J,358.3,4712,2)
 ;;=^60635
 ;;^UTILITY(U,$J,358.3,4713,0)
 ;;=252.01^^45^387^16
 ;;^UTILITY(U,$J,358.3,4713,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4713,1,4,0)
 ;;=4^HYPERPARATHYROID,PRIMARY
 ;;^UTILITY(U,$J,358.3,4713,1,5,0)
 ;;=5^252.01
 ;;^UTILITY(U,$J,358.3,4713,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,4714,0)
 ;;=252.02^^45^387^17
 ;;^UTILITY(U,$J,358.3,4714,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4714,1,4,0)
 ;;=4^HYPRPRTHYRD NONRENAL,SEC
 ;;^UTILITY(U,$J,358.3,4714,1,5,0)
 ;;=5^252.02
 ;;^UTILITY(U,$J,358.3,4714,2)
 ;;=^331440
 ;;^UTILITY(U,$J,358.3,4715,0)
 ;;=794.6^^45^388^1
 ;;^UTILITY(U,$J,358.3,4715,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4715,1,4,0)
 ;;=4^ABN ENDOCRINE STUDY NEC
 ;;^UTILITY(U,$J,358.3,4715,1,5,0)
 ;;=5^794.6
 ;;^UTILITY(U,$J,358.3,4715,2)
 ;;=^273448
 ;;^UTILITY(U,$J,358.3,4716,0)
 ;;=783.1^^45^388^2
 ;;^UTILITY(U,$J,358.3,4716,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4716,1,4,0)
 ;;=4^ABNORMAL WEIGHT GAIN
 ;;^UTILITY(U,$J,358.3,4716,1,5,0)
 ;;=5^783.1
 ;;^UTILITY(U,$J,358.3,4716,2)
 ;;=^998
 ;;^UTILITY(U,$J,358.3,4717,0)
 ;;=780.53^^45^388^13
 ;;^UTILITY(U,$J,358.3,4717,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4717,1,4,0)
 ;;=4^SLEEP APNEA W/ HYPERSOMNIA
 ;;^UTILITY(U,$J,358.3,4717,1,5,0)
 ;;=5^780.53
 ;;^UTILITY(U,$J,358.3,4717,2)
 ;;=^332925
 ;;^UTILITY(U,$J,358.3,4718,0)
 ;;=780.57^^45^388^12
 ;;^UTILITY(U,$J,358.3,4718,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4718,1,4,0)
 ;;=4^SLEEP APNEA W/ DISTURB
 ;;^UTILITY(U,$J,358.3,4718,1,5,0)
 ;;=5^780.57
 ;;^UTILITY(U,$J,358.3,4718,2)
 ;;=^332928
